[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100458741":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":32,"locations":41,"responsibleParty":62,"collaborators":10,"id":65,"slug":10,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":10,"eligibilityCriteria":69,"healthyVolunteers":70,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":10,"studyType":77,"phases":10,"briefSummary":78,"conditions":79,"keywords":10,"overallStatus":44,"whyStopped":10,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Shaare Zedek Medical Center","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Carriers of Gaucher disease",null,"Family of patients with Gaucher disease, sequenced for the GBA1 gene.",[13],"Diagnostic Test: The investigators aim to identify prodromal PD in a cohort of carriers of Gaucher disease.",{"label":15,"type":10,"description":16,"interventionNames":17},"Gaucher patients","Patients from the Gaucher clinic in Shaare Zedek Medical Center, Jerusalem, Israel",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Healthy controls","Family members of Gaucher patients who are not carriers of Gaucher disease",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"DIAGNOSTIC_TEST","The investigators aim to identify prodromal PD in a cohort of carriers of Gaucher disease.","Tests to help identify prodromal PD in a cohort of carriers of Gaucher disease",[9,15,19],[29],{"name":30,"affiliation":5,"role":31},"Ari Zimran, MD","PRINCIPAL_INVESTIGATOR",[33,37],{"name":30,"role":34,"phone":35,"phoneExt":10,"email":36},"CONTACT","+972-509149149","azimran@gmail.com",{"name":38,"role":34,"phone":39,"phoneExt":10,"email":40},"Michal Becker- Cohen, M.Sc.","+972-504606310","michalbec@gmail.com",[42],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Michal Becker- Cohen","RECRUITING","Jerusalem","Please Select...","9103102","Israel",{"type":50,"coordinates":51},"Point",[52,53],35.21633,31.76904,{"lat":53,"lon":52},[56,59,60],{"name":57,"role":34,"phone":58,"phoneExt":10,"email":36},"Ari Zimran, M.D.","+97226555143",{"name":38,"role":34,"phone":58,"phoneExt":10,"email":40},{"name":61,"role":31,"phone":10,"phoneExt":10,"email":10},"Ari Zimran, Prof.",{"type":31,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Ari Zimran","Prof.","100458741",false,"NCT05253560","Prodromal Parkinsonian Features in GBA1 Mutation Carriers","Inclusion Criteria:\n\n* Willing to participate\n\nExclusion Criteria:\n\n* PD patients\n* Dementia",true,"ALL","40 Years","75 Years",{"count":75,"type":76},600,"ESTIMATED","OBSERVATIONAL","Objective of the trial. To define a sub-population which is at increased risk of developing Parkinson, beyond the fact of carrying Gaucher; in this sub-population the investigators shall conduct a comprehensive evaluation that includes a variety of non-invasive tests, whose purpose is to evaluate the state of the pre- Parkinson's disease signs, signs which can appear, even twenty years before the appearance of the disease, and also to compare them to a group of diagnosed Gaucher patients and a group of healthy people who are not carriers of Gaucher disease.\n\nA group of those carriers will be available for trial or for treatment, if there will be a medicine for the prevention of the development of Parkinson, obtainable.",[80,81],"Gaucher Disease, Type 1","Healthy","2026-04-23",{"date":84,"type":85},"2026-04-29","ACTUAL",{"date":87,"type":85},"2017-05-16",{"date":89,"type":76},"2030-12-31",{"name":5,"class":6},1]